title: Fcgamma receptor IIa, IIIa, and IIIb polymorphisms of systemic lupus erythematosus in Taiwan.
abstract: OBJECTIVE
  To determine whether the distribution of Fcgamma receptor IIa, IIIa, and IIIb polymorphisms confers a risk factor for disease susceptibility, and correlates with the clinical characteristics and serological parameters of patients with SLE in Taiwan.
  
  
  METHODS
  Genotyping of Fcgamma receptors IIa H/R131, IIIa F/V158, and IIIb NA1/NA2 was performed in 302 patients with SLE and 311 healthy blood donor controls. The distribution of Fcgamma receptor IIa, IIIa, and IIIb genotypes in patients and controls was analysed. Frequencies of three Fcgamma receptor polymorphisms were also compared between lupus patients with and without different clinical manifestations and autoantibodies.
  
  
  RESULTS
  No significant skewing in the distribution of Fcgamma RIIa H/R131, Fcgamma RIIIa F/V158, and Fcgamma RIIIb NA1/NA2 was found between patients and controls in Taiwan. The following clinical associations were found: Fcgamma RIIIb NA1/NA1 protected against neuropsychiatric lupus (p = 0.028) but conferred susceptibility to discoid rash (p<0.005); increased Fcgamma RIIIa V/V158 was associated with infections (p = 0.039); increased Fcgamma RIIa H/H131 was associated with earlier onset of lupus (p = 0.01).
  
  
  CONCLUSIONS
  Fcgamma receptor IIa, IIIa, and IIIb polymorphisms may be responsible for the development of distinct manifestations of lupus patients in Taiwan, but there is no significantly skewed distribution in the susceptibility to lupus as a whole.
authors.affiliation: Department of Medicine, Division of Allergy, Immunology and Rheumatology, Chang Gung Memorial Hospital, No 5 Fu-Shin St, Kuei-Shan, Tao-Yuan, Taiwan, Republic of China.
authors.forename: J-Y
authors.initials: JY
authors.lastname: Chen
authors.forename: C M
authors.initials: CM
authors.lastname: Wang
authors.forename: K-C
authors.initials: KC
authors.lastname: Tsao
authors.forename: Y-H
authors.initials: YH
authors.lastname: Chow
authors.forename: J-M
authors.initials: JM
authors.lastname: Wu
authors.forename: C-L
authors.initials: CL
authors.lastname: Li
authors.forename: H-H
authors.initials: HH
authors.lastname: Ho
authors.forename: Y-J Jan
authors.initials: YJ
authors.lastname: Wu
authors.forename: S-F
authors.initials: SF
authors.lastname: Luo
mesh_terms: D000328:Adult; D001323:Autoantibodies / Q000097:blood; D016022:Case-Control Studies; D016009:Chi-Square Distribution; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D007239:Infections / Q000209:etiology; D008180:Lupus Erythematosus, Systemic / Q000175:diagnosis / Q000235:genetics* / Q000276:immunology; D008875:Middle Aged; D011110:Polymorphism, Genetic; D017452:Receptors, IgG / Q000235:genetics*; D018570:Risk Assessment; D013624:Taiwan
chemical_list: D001323:Autoantibodies; D017452:Receptors, IgG